ECSP10010224A - Formulaciones líquidas de hormona luteinizante (lh). - Google Patents

Formulaciones líquidas de hormona luteinizante (lh).

Info

Publication number
ECSP10010224A
ECSP10010224A EC2010010224A ECSP10010224A ECSP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC 2010010224 A EC2010010224 A EC 2010010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A
Authority
EC
Ecuador
Prior art keywords
luteinizing hormone
liquid formulations
hormone liquid
administration
luteinizing
Prior art date
Application number
EC2010010224A
Other languages
English (en)
Spanish (es)
Inventor
Rita Agostinetto
Fabrizio Samaritani
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of ECSP10010224A publication Critical patent/ECSP10010224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EC2010010224A 2007-11-01 2010-05-31 Formulaciones líquidas de hormona luteinizante (lh). ECSP10010224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28

Publications (1)

Publication Number Publication Date
ECSP10010224A true ECSP10010224A (es) 2010-07-30

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010224A ECSP10010224A (es) 2007-11-01 2010-05-31 Formulaciones líquidas de hormona luteinizante (lh).

Country Status (25)

Country Link
US (1) US8664369B2 (cg-RX-API-DMAC7.html)
EP (1) EP2219607B1 (cg-RX-API-DMAC7.html)
JP (1) JP5551601B2 (cg-RX-API-DMAC7.html)
KR (1) KR101513181B1 (cg-RX-API-DMAC7.html)
CN (1) CN101842083B (cg-RX-API-DMAC7.html)
AU (1) AU2008320844B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818324B8 (cg-RX-API-DMAC7.html)
CA (1) CA2700662C (cg-RX-API-DMAC7.html)
CY (1) CY1113121T1 (cg-RX-API-DMAC7.html)
DK (1) DK2219607T3 (cg-RX-API-DMAC7.html)
EA (1) EA019432B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010224A (cg-RX-API-DMAC7.html)
ES (1) ES2393233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120660T1 (cg-RX-API-DMAC7.html)
IL (1) IL205105A (cg-RX-API-DMAC7.html)
MX (1) MX2010004639A (cg-RX-API-DMAC7.html)
MY (1) MY153976A (cg-RX-API-DMAC7.html)
NZ (1) NZ583991A (cg-RX-API-DMAC7.html)
PL (1) PL2219607T3 (cg-RX-API-DMAC7.html)
PT (1) PT2219607E (cg-RX-API-DMAC7.html)
RS (1) RS52566B (cg-RX-API-DMAC7.html)
SI (1) SI2219607T1 (cg-RX-API-DMAC7.html)
UA (1) UA101484C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009056569A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001907B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
PL3228320T3 (pl) 2008-10-17 2020-06-01 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
TWI520745B (zh) * 2009-07-06 2016-02-11 賽諾菲阿凡提斯德意志有限公司 含甲硫胺酸之胰島素製劑
SI2498801T1 (en) 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
CA3011480C (en) 2009-11-13 2021-11-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
NZ707168A (en) * 2012-12-26 2016-09-30 Wockhardt Ltd Pharmaceutical composition of insulins
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
UA61053C2 (en) * 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
NZ508874A (en) * 1998-07-23 2004-03-26 Lilly Co Eli FSH and FSH variant formulations, products and methods of treating infertility.
EP1599222B1 (en) * 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Also Published As

Publication number Publication date
JP2011502968A (ja) 2011-01-27
BRPI0818324A2 (pt) 2017-05-16
CN101842083B (zh) 2012-11-14
NZ583991A (en) 2012-02-24
CA2700662C (en) 2015-10-13
HRP20120660T1 (hr) 2012-09-30
AU2008320844A1 (en) 2009-05-07
MY153976A (en) 2015-04-30
RS52566B (sr) 2013-04-30
AU2008320844B2 (en) 2013-08-29
CN101842083A (zh) 2010-09-22
MX2010004639A (es) 2010-08-04
EP2219607B1 (en) 2012-08-15
JP5551601B2 (ja) 2014-07-16
US20100261649A1 (en) 2010-10-14
KR20100088147A (ko) 2010-08-06
PT2219607E (pt) 2012-08-31
EA201070549A1 (ru) 2010-10-29
PL2219607T3 (pl) 2012-12-31
BRPI0818324B8 (pt) 2021-05-25
US8664369B2 (en) 2014-03-04
DK2219607T3 (da) 2013-06-17
HK1145443A1 (en) 2011-04-21
WO2009056569A1 (en) 2009-05-07
ZA201001907B (en) 2011-05-25
BRPI0818324B1 (pt) 2019-12-24
SI2219607T1 (sl) 2012-09-28
CY1113121T1 (el) 2016-04-13
ES2393233T3 (es) 2012-12-19
UA101484C2 (en) 2013-04-10
IL205105A0 (en) 2010-11-30
EA019432B1 (ru) 2014-03-31
IL205105A (en) 2015-04-30
KR101513181B1 (ko) 2015-04-21
CA2700662A1 (en) 2009-05-07
WO2009056569A9 (en) 2010-01-21
EP2219607A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
PE20090607A1 (es) Formulacion farmaceutica de dispersion liposomal en polvo seco
EA201170512A1 (ru) Композиция для перорального введения
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EP3784214C0 (en) ORAL LIQUID PHARMACEUTICAL DOSAGE FORM
TN2015000135A1 (en) Modified release formulations for oprozomib
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
ECSP088850A (es) Formulación de medicamento líquida
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
ES2325291A1 (es) "uso de un extracto de silybum marianum"
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico